卵巢癌筛查——超声对卵巢癌死亡率的影响
本文综述卵巢癌筛查策略,聚焦经阴道超声及CA-125算法单独或联合应用。经阴道超声可识别卵巢大小和形态变化,但特异性低;筛查对卵巢癌死亡率的影响尚不明确,需进一步验证。多数前瞻性试验(PLCO除外)报告检出时分期降低,但尚无研究能确证筛查人群总死亡率下降。
要点
- 经阴道超声可识别卵巢大小和形态变化,但被指特异性低。
- 多数前瞻性试验(PLCO除外)报告检出时分期降低。
- 尚无研究能确证筛查降低卵巢癌死亡率,需进一步验证。
核心结论
- 筛查对卵巢癌死亡率的影响尚不明确,需进一步验证;已有初步证据提示筛查可改善生存。
- 尽管已有多项已发表的前瞻性研究,迄今尚无研究能确证筛查可降低一般人群或高危人群的卵巢癌死亡率。
研究设计与样本
- 综述文章,讨论卵巢癌筛查项目的争议及超声对降低卵巢癌相关死亡率的影响。
- 最广泛测试的筛查策略为经阴道超声及测量血清癌抗原-125水平或间隔变化的算法,单独或联合应用。
关键影像表现/征象
- 经阴道超声可识别可能提示恶性病变的卵巢大小和形态变化。
- 经阴道超声仍被指特异性低。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 经阴道超声仍被指特异性低。
- 筛查对卵巢癌死亡率的影响尚不明确,需进一步验证。
- 尽管已有多项已发表的前瞻性研究,迄今尚无研究能确证筛查可降低一般人群或高危人群的卵巢癌死亡率。
- 美国前列腺、肺、结直肠和卵巢(PLCO)癌症筛查试验的数据未显示一般人群的生存或死亡率获益。
- 多数前瞻性试验报告检出时分期降低(PLCO试验除外)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Although ovarian cancer (OC) is the most lethal of all female malignancies, debate still exists concerning the benefits and harms of the screening programs and their impact on long-term survival and mortality from the disease. The most widely tested screening strategies have focused on transvaginal ultrasound (TVU) and on algorithms that measure serum levels or interval changes of cancer antigen-125 (CA-125) either individually or in combination. Transvaginal ultrasound can identify size and morphology changes of the ovary that may signal a developing malignancy; yet, it is still accused of having a low specificity. There is preliminary evidence that screening can improve survival, but the impact of screening on mortality from OC is still unclear and warrants further validation. In spite of having many published prospective studies, up to-date, none have been able to demonstrate conclusively a reduction in mortality from OC both in the screened general or high-risk population. Data from the US Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial has not shown survival or mortality benefits in the general population. Most prospective trials have reported a decrease in stage at detection (with the exception of the PLCO trial), thereby allowing treatment to be initiated when the disease is most curable. Research is in progress to develop new diagnostic tests and novel biomarkers, which when used in combination can increase the accuracy and outcomes of screening. In this review article, we will discuss the debate provoked on OC screening programs and the impact of using ultrasound on the reduction of OC-related mortality.
引用
- Kamal R, Hamed S, Mansour S, et al. Ovarian cancer screening-ultrasound; impact on ovarian cancer mortality. Br J Radiol. 2018. PMID: 30102555. doi:10.1259/bjr.20170571
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。